Xenon To Present At Upcoming Investor Conferences
Date
11/13/2024 4:16:43 PM
(MENAFN- GlobeNewsWire - Nasdaq) VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.
Stifel 2024 Healthcare conference on Monday, November 18, 2024 at 9:10 a.m. ET (webcast LINK ) Jefferies London Healthcare Conference 2024 on Wednesday, November 20, 2024 at 1:30 PM GMT / 8:30 am ET (webcast link )
Details about company presentations, webcasts, and other events can be found on the“Investors” section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
...
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
...
MENAFN13112024004107003653ID1108883342
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.